Integra LifeSciences (NASDAQ:IART) Releases Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share guidance of $0.81-0.89 for the period, compared to the consensus earnings per share estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on IART shares. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Morgan Stanley lifted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Citigroup dropped their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. Finally, JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $26.50.

Integra LifeSciences Price Performance

NASDAQ:IART traded up $0.31 during mid-day trading on Tuesday, hitting $24.43. 183,678 shares of the stock traded hands, compared to its average volume of 1,094,289. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a market cap of $1.90 billion, a PE ratio of 83.17, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08. The business’s 50-day moving average price is $18.62 and its 200 day moving average price is $24.46.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. Integra LifeSciences’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.76 EPS. On average, analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.